Founded in 2011 by Frank Yu, Ally Bridge Group is a Hong Kong based investment group. They focus their investments in the healthcare sector in the United States, Europe and China. Their investments come at growth stage, late-stage, buyout or they will invest in hedge funds.
For their growth and late stage investments, Ally Bridge Group looks to invest in healthcare companies focused on pharmaceuticals and medical devices with near-term liquidity events or exits. For buyouts or large growth capital, they look to invest in cross-border healthcare companies or China-based healthcare companies with cross-border aspirations.
Ally Bridge Group has invested in WuXi AppTec, Grail, WuXi NextCode, Medtech, Shockwave Medical, NxThera, Quantum Surgical, Jinxin Fertility, Pulmonx, Duoning Biotech, GenFleet Therapeutics, Akeso Biopharma, Quantum Surgical, Innovent Biologics and Hua Medicine.
Grail is a biotechnology company headquartered in Menlo Park, California that was founded as a spinoff of Illumina Inc and initially headed by Jeffrey Huber in 2016, focused on making a medical device that can detect early stage cancer.
A pharmaceutical company developing treatments for cancer and chronic diseases. It was founded in 2006 and is located in San Diego, California.
Develops medicines for patients suffering from Alzheimer's disease and other neurological disorders.
A company developing therapeutic probiotics that alter the human gut microbiome to treat diseases.
Tesaro is a biopharmaceutical company focused on identifying cancer therapies, acquired by GSK in 2019.
Akeso Biopharma is a biotechnology and biopharmaceutical company focused on the research and development of new pharmaceutical products and founded in 2012.
A biopharmaceutical company focused on developing treatments for inner and middle ear diseases
Goldfinch Bio is a Cambridge, Massachusetts-based biotechnology company.
Cyteir Therapeutics is a Cambridge, Massachusetts-based company.
Goldfinch Biopharma is a Cambridge, Massachusetts-based therapeutics company focused on discovering and developing precision therapies for patients with kidney disease.
Charles Chon, CFA
Partner and Managing Director
Founder, CEO, CIO
Hong Zheng, PhD
Tinnie Chau, CFA